[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Precigen Inc (PGEN)

Precigen Inc (PGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices

GERMANTOWN, Md. and FORT WORTH, Texas , June 11, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative...

PGEN : 4.73 (-0.42%)
Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

GERMANTOWN, Md. , May 30, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines...

PGEN : 4.73 (-0.42%)
Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States

GERMANTOWN, Md. , May 27, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve...

PGEN : 4.73 (-0.42%)
Precigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare Conference

GERMANTOWN, Md. , May 26, 2026 /PRNewswire/ -- Precigen, Inc.  (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines...

PGEN : 4.73 (-0.42%)
Precigen Q1 Earnings Call Highlights

Precigen (NASDAQ:PGEN) reported a sharp increase in first-quarter 2026 revenue as the company’s first commercial product, PAPZIMEOS, continued its U.S. launch following FDA approval in August 2025.On...

PGEN : 4.73 (-0.42%)
Precigen Reports First Quarter 2026 Financial Results and Business Updates

GERMANTOWN, Md. , May 13, 2026 /PRNewswire/ --  Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines...

PGEN : 4.73 (-0.42%)
Precigen's First Commercial Quarter Will Test Whether PAPZIMEOS Revenue Can Justify the Pivot

Barchart Research What to Expect from PGEN Earnings PGEN Generated May 12, 2026 Current Price $4.08 EPS Estimate $$-0.03 Consensus Rating Moderate Buy Average Move 9.60% Precigen's First Commercial Quarter...

PGEN : 4.73 (-0.42%)
Precigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 13

GERMANTOWN, Md. , May 7, 2026 /PRNewswire/ --  Precigen, Inc.  (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines...

PGEN : 4.73 (-0.42%)
Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31

GERMANTOWN, Md. , March 30, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines...

PGEN : 4.73 (-0.42%)
Precigen Reports Full Year 2025 Financial Results and Business Updates

GERMANTOWN, Md. , March 25, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines...

PGEN : 4.73 (-0.42%)

Barchart Exclusives

Citigroup’s Dividend Yield Now Trails Its Peers, But I’m Still Bullish
Citigroup's dividend yield has fallen steeply as its stock has soared over the last three years. Is the stock still a buy? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.